RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group - Gilde Healthcare

Menu
Menu
Home

RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group

January 19, 2021

Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group.

Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in and around Lahnstein and provide imaging services to several local hospitals.

RAD-x is pleased to see its Partnership model confirmed by the integration of RZL and expects to further accelerate the growth of its platform structure in 2021.

 

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over $1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, MedTech and therapeutics. The venture & growth companies are based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.

More news

Gilde Healthcare launches Climate Solutions fund realizing initial close at €250M

With commitments from international pension funds, banks, fund-of-funds, endowments and family offices, Gilde Healthcare realizes an initial close at €250 million Expansion into Climate Solutions builds on Gilde Healthcare’s track record in impactful investing and...
February 18, 2026

Gilde Healthcare Company Big Health Secures Funding to Accelerate Adoption of Digital Mental Health Treatments

New investment fuels expansion as leading health systems adopt evidence-based digital care, driven by new billing codes and strong demand for proven mental health solutions. Big Health, a leading developer of digital treatments for the...
February 12, 2026

Gilde Healthcare company SpyGlass Pharma announces pricing of initial public offering at NASDAQ

SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per...
February 6, 2026